🇺🇸 FDA
Pipeline program

ARCT-021 single dose priming

ARCT-021-04

Phase 2 mab terminated

Quick answer

ARCT-021 single dose priming for Covid19 is a Phase 2 program (mab) at Arcturus Therapeutics Holdings with 1 ClinicalTrials.gov record(s).

Program details

Company
Arcturus Therapeutics Holdings
Indication
Covid19
Phase
Phase 2
Modality
mab
Status
terminated

Clinical trials